Rahul Matthan: Indian genes could save the world from rare diseases
Rahul Matthan India offers a treasure trove of genetic data for AI-enabled researchers to develop therapies neglected by commercial drug-makers for insufficient demand. India could take a global lead in this sphere, with a big role played by data from its many endogamous communities. India has over 350 endogamous communities. Gift this article
In an episode of my podcast titled 'The Incurable Disease,' I told of how a husband and wife with no previous medical training or experience built a genetics laboratory in a bungalow in Bangalore so they could find a treatment for Duchenne's Muscular Dystrophy (DMD) to save their son. As much as this is a story of grit and perseverance, it also shows how far genetic technology has come and how affordable its innovations can now be.
In an episode of my podcast titled 'The Incurable Disease,' I told of how a husband and wife with no previous medical training or experience built a genetics laboratory in a bungalow in Bangalore so they could find a treatment for Duchenne's Muscular Dystrophy (DMD) to save their son. As much as this is a story of grit and perseverance, it also shows how far genetic technology has come and how affordable its innovations can now be.
Diseases like DMD are rare medical conditions. They affect a relatively small proportion of the general population. Yet, over 400 million people suffer from more than 7,000 known rare diseases today, with the Global South bearing the bulk of this burden.
While there are treatments for many rare diseases, given the small size of the patient population, pharmaceutical companies cannot achieve the economies of scale needed to make them commercially available. In the 1980s, patient advocacy groups began to draw attention to this, pointing out that research and development (R&D) for rare disease drugs was being discouraged because it wasn't profitable. Since they were being consciously abandoned, they started being called 'orphan drugs.'
Since most rare diseases are of genetic origin, they can be treated using genetic and gene-editing science. Ever since the Human Genome Project was completed in 2003, the cost of genomic sequencing has fallen dramatically. From the approximately $2.7 billion that it took at that time to sequence the first human genome, it now costs less than $100. This has made it possible for us to develop treatments for genetic diseases at a relatively affordable cost.
Since that podcast episode, I've come across several other examples of frugal genetic innovation in India. The Centre for Stem Cell Research at the Christian Medical College, Vellore, has successfully used 'lentiviral vectors' to treat patients suffering from Haemophilia-A, and India's first clinical trial for sickle cell disease (SCD) using indigenous technology could become the first Crispr-based corrective therapy for the disease.
Each of these treatments costs much less than their Western counterparts; India's Crispr-based cure for SCD costs between $25,000 and $100,000 per patient versus about $2.2 million in the West. This demonstrates that India not only has the technical ability to find treatments, it can do so affordably.
This, in large part, is because of how India's regulatory framework has evolved in support of these initiatives, with the Indian Council of Medical Research guidelines for cell and gene therapies providing clear pathways for innovation. The National Policy for Rare Diseases, announced in 2021, provides further support to this ecosystem by offering financial aid and establishing centres of excellence. In addition, various state subsidies and manufacturing initiatives for critical components like delivery vectors and stem cells have contributed to cost reductions.
Also Read: Genetic studies: Let's cast a wider DNA net
While developed countries in the West have advanced R&D capabilities, they lack genetic diversity in disease models. As a result, they struggle to find suitable cohorts of patients suffering from rare diseases. This has hindered the design of clinical trials as well as the timely treatment of patients, particularly in the case of early-onset diseases.
India, on the other hand, has over 350 endogamous communities. As a result, the country has a high rate of consanguinity. This has resulted in a high prevalence of recessive gene mutations in the population, presenting unique opportunities for genetic discovery and insights into disease biology.
Given that Indian scientists have demonstrated their ability to develop commercially viable treatments for rare genetic disorders, India can play an important role in using interventional genomics to find cost-effective cures for rare diseases.
This, according to a recent article in The CRISPR Journal, is an opportunity to establish a first-of-its-kind North-South collaboration that could offer lasting solutions to the problem of rare diseases in a way that benefits everyone. The article proposes the establishment of a platform that will 'bridge scientific, clinical, and economic gaps" and, in the process, leverage India's genetic diversity to offer a shared opportunity for therapeutic innovation.
Also Read: Gene editing: Is humanity ready to rewrite the book of life?
The first step in this direction would be the creation of comprehensive data infrastructure to capture clinical, genomic and bio-sample data from rare disease patients in India. With this in place, we can deploy an analysis engine powered by AI to enable clinical trial matching and advanced analytics for gene discovery and disease biology insights using the best technologies from the Global North.
The resulting platform should be able to quickly analyse Crispr drug candidates and optimally guide delivery systems and dosage calibrations in subsequent preclinical research and clinical trials. It would also establish the quality standards and safety data needed to manufacture specialized biological components, ensuring that they meet the same rigorous standards as any regulated therapeutic solution.
The platform approach will position India as an equal partner in the creation of a future in which medical treatment is personalizable, precise and, above all, widely accessible. It would also transform India's endogamous communities, once characterized by their genetic risk, into co-inventors of cures that the world still lacks.
The author is a partner at Trilegal and the author of 'The Third Way: India's Revolutionary Approach to Data Governance'. His X handle is @matthan. Topics You May Be Interested In Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Carlyle to buy major stake in Knack Global
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Mumbai: Private equity (PE) fund Carlyle Group has signed an agreement to acquire a significant majority stake in Knack Global , a Florida-based revenue cycle management (RCM) solutions provider, at a valuation of around $500 million, people aware of the deal told exact quantum of the stake could not be in 2007 by Rajiv Sharma in Mohali, Knack employs more than 3,800 healthcare experts and caters to providers across categories including physician groups, hospitals, ambulatory care centres, surgical facilities, and durable medical equipment suppliers. The company has a strong global footprint, with offices in Mohali, Mumbai, Hyderabad and Jaipur, besides four offices across the by investors such as LKCM Headwater Investments, Weave Growth, and angel investor Anurag Jogindernath Wahi, Knack Global raised its last funding in a seed round in 2022, according to firm appointed Arvind Ramakrishnan as CEO in May 2024, who joined from 8D Consulting Inc., bringing deep experience advising private equity firms on healthcare technology and services.A Carlyle spokesperson declined to comment while mails sent to Knack Global did not elicit any responses till the press to BCC Research, the global healthcare BPO market is projected to grow from $151.9 billion in 2022 to $259.5 billion by 2028, at a CAGR of 9.7%.The RCM industry has become a prime investment destination for global funds, driven by rising outsourcing demand from US healthcare providers. Increasing billing complexity, tightening compliance requirements, and the need to improve patient experience have pushed hospitals and physician groups to partner with specialist RCM firms. Outsourcing allows them to cut costs, improve efficiency, and ensure faster Knack Global deal is part of a broader wave of consolidation in the $259-billion healthcare outsourcing market. In 2024, Carlyle was in the race to acquire Chennai and Texas-based RCM service provider Access Healthcare , before US fund New Mountain Capital clinched the deal at a valuation of $1.8-2 billion, outbidding Blackstone, TPG and recent large-ticket deals include Blackstone's $1.1-billion acquisition of AGS Health, Ontario Teachers' Pension Plan's 45% stake buy in Omega Healthcare valuing it at $1.8 billion, TA Associates' $250 million majority buyout of Vee Healthtek, and EQT Partners' $860-million acquisition of GeBBS Healthcare Solutions from complexity of healthcare billing and reimbursement regulations, the growing focus on improving patient experience and the need for efficient and cost-effective revenue cycle management processes, are some of the key factors that are driving the healthcare revenue cycle management market, according to a study by Precedence Statistics.
Indian Express
5 hours ago
- Indian Express
How right-wing outcry influenced US pausing visitor visas for Gazans
Written by Hamed Aleaziz and Ken Bensinger The Trump administration announced Saturday that it had paused approvals of visitor visas for people from the Gaza Strip, a key pathway for those seeking medical care in the United States, including young children who arrived in recent weeks with serious conditions. The State Department said it would assess the process behind those visas. 'All visitor visas for individuals from Gaza are being stopped while we conduct a full and thorough review,' the department said in a statement on the social platform X on Saturday morning. Palestinians coming to the US The move came after an intense lobbying campaign by right-wing activist Laura Loomer, who called the incoming flights a 'national security threat' in a flurry of social media posts starting Friday that targeted a nonprofit aiding in medical evacuations. Just weeks ago, the nonprofit, HEAL Palestine, an Ohio-based group that helps Palestinian families and children, began orchestrating what it called the 'largest single medical evacuation of injured children from Gaza to the U.S.,' bringing injured and ill children from Gaza to the United States for care. To date, the group says it has evacuated 63 injured children for treatment, including 11, from age 6 to 15, who were flown to hospitals in nine U.S. cities this month. Many of the children had lost limbs during the conflict in Gaza. They are expected to travel to Egypt to rejoin their families once their medical care is completed, according to HEAL Palestine. The group, which was founded last year and also operates food kitchens in Gaza, did not respond to requests for comment. Earlier this month, Dr. Zeena Salman, a co-founder of HEAL Palestine, said in a statement that the medical evacuation flights were a matter of life or death. 'These children could not wait,' Salman said. 'Their lives are at stake, and this mission is about giving them a future.' Julia Gelatt, the associate director of the U.S. immigration policy program at the Migration Policy Institute, said that more than 9,000 people with travel documents from the Palestinian Authority had entered the United States on visitor visas in the 2024 fiscal year. 'This move is consistent with the Trump administration's overall treatment of immigrants as constituting a threat to U.S. public safety,' Gelatt said. 'But it is extremely hard to imagine how someone coming to the U.S. for lifesaving medical treatment would present a national security risk.' Loomer, who wields extraordinary power in shaping Trump administration decisions over personnel and policy despite not having an official role in government, said she first learned of the flights earlier this month. 'I felt like this is something that needs attention,' she said in an interview. 'Under the Trump administration, they are actively importing Gazans into the U.S. Clearly this is not what we voted for.' On social media, Loomer called attention to a video posted Aug. 6 by HEAL Palestine, showing Palestinian children arriving at the San Francisco airport. She subsequently posted about flights to St. Louis, San Antonio and Houston and claimed without providing evidence that the nonprofit was connected to Hamas, tagging state and federal officials in her posts. Rep. Chip Roy, R-Texas, responded to her late Friday on X that he was 'deeply concerned about the incoming flights' and was making inquiries. Loomer said she spoke with Secretary of State Marco Rubio on Friday night to alert him to the flights and what she called the threat of an Islamic invasion. The State Department did not respond to a request for comment. Those impacted the most Loomer has a long history of anti-Islam activism. In 2017, she wrote a social media post that cheered the drowning deaths of 2,000 refugees who were trying to flee violence in Syria and other countries with large Muslim populations by crossing the Mediterranean. For years, she has pushed for the Muslim Brotherhood, the Sunni Islamist movement, to be designated as a terrorist organization by the U.S. government, lobbying both members of Congress and the administration. Last week, Rubio said such a designation from the State Department was 'in the works.' Medical flights for children affected by the conflict in Gaza have been occurring for well over a year, organized by a variety of charities. Dr. Mohammad Subeh, an emergency room physician who volunteers for HEAL Palestine, said that he had previously treated some of the children who recently arrived in the San Francisco Bay Area during his time in Gaza. He said that the injuries included orthopedic trauma and severe burns and that they were exacerbated by malnutrition. 'I am saddened to see fear and hate permeate within a small yet vocal segment of our society, whereby people have dehumanized children,' he said, by pushing for policies to withhold 'life- and limb-saving care.' Andrew Miller, a former senior State Department official on Israeli-Palestinian affairs in the Biden administration, said that Gaza residents could only get visas to the U.S. by appearing at an embassy in Jerusalem, Cairo or Amman, Jordan, and undergo security checks. 'What's more, just to get to a U.S. Embassy outside of Gaza, the Israeli military and security services had to clear them and anyone accompanying them,' he said, adding: 'From what I saw, any insinuation that we were taking an unusual security risk in these cases is baseless.' This article originally appeared in The New York Times.
The Hindu
5 hours ago
- The Hindu
Free medical camp at Srisailam on August 18
A free medical camp will be held at the Srisailam temple hospital on August 18 (Monday) for the benefit of locals and devotees visiting the shrine. Expert doctors in general medicine, orthopedics, neurology and others will conduct tests and provide medicines free of cost. Paediatricians would also be available and medicines will be provided free after tests. Srisailam temple executive office (EO) M. Srinivasa Rao said Tadipatri-based M. Mallikarjuna Naidu has arranged the medical camp.
